Drugs / GX-G6
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03651466 | Aug 2017 → Jun 2018 | diabetes mellitus | Genexine, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03962010 | Jun 2019 → Jun 2022 | type 2 diabetes mellitus | Genexine, Inc. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2019-07-05 | Genexine, Inc. | Regulatory GX-G6, a long-acting diabetes treatment, is approved for phase 2 clinical trials in Australia genexine.com ↗
Genexine, an innovative new drug development company, has approved the clinical trial phase 2 plan for the long-acting diabetes treatment drug'GX-G6' from Australia's'Therapeutic Goods Adminstration' (TGA) and'Herman Research Ethics Committees' (HREC) of the site. |
| 2017-01-18 | Genexine, Inc. | Regulatory GX-G6 for Type 2 Diabetes, Receives Phase I IND Approval in Europe genexine.com ↗
GX-G6, long-acting glucagon-like peptide-1 (GLP-1), received Phase I IND approval from The Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) in Germany. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-07-05 | Genexine, Inc. | GX-G6, a long-acting diabetes treatment, is approved for phase 2 clinical trials in Australia genexine.com ↗ |
| 2017-01-18 | Genexine, Inc. | GX-G6 for Type 2 Diabetes, Receives Phase I IND Approval in Europe genexine.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gx-G6 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03651466 ↗ |
| Route | Subcutaneous | “Single Subcutaneously Administered GX-G6” NCT03651466 ↗ |